Deschler-Baier et al. reported on 6 PCC patients treated with selpercatinib in the LIBRETTO-001 study, a global phase 1/2 multicohort clinical trial involving 41 patients with solid tumors harboring an activating RET variant other than NSCLC and thyroid cancer [16]. The gene discussed is RET; the disease is thyroid cancer.